Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  
Google
Web www.equitybulls.com
Research

| More

ICICI Prudential Life Insurance - Business momentum upwards; valuations remain attractive - ICICI Securities

Posted On: 2021-04-20 11:05:42 (Time Zone: UTC)


The big strategic achievement from FY21 for ICICI Prudential Life Insurance (IPRU) is the establishment of an ex-ICICI Bank product as well as distribution capability. Key effects of this strategy include: (1) Growth in non-linked savings portfolio by healthy 56% YoY in FY21, (2) introduction of guaranteed savings as well as deferred annuity products and (3) spurt in new distribution channels with ~600 partnerships including 23 banks and > 185,000 advisors. As such, despite ICICI Bank's contribution declining to 31% of the overall APE which in turn declined 13% YoY, total FY21 VNB was flat at Rs16bn. Management aims to increase annual VNB by Rs10bn over FY22-23 (implied CAGR of 27%). Considering the turnaround in business momentum and attractive valuations (1.8x based on FY23E EV of Rs366bn), we upgrade the stock from Add to BUY.

- Becoming more diversified than peers? The question is absolutely pertinent for IPRU considering its current mix of distribution and products and VNB contribution. The company appears better prepared for more bottom-up approach to follow a demand-based business strategy as it offers the entire bouquet of retail protection, group term, credit life, annuities, linked as well as traditional segments. The distribution mix (APE terms) of FY21 stood at banca (ICICI Bank): 31%, banca (others): 11%, agency:24%, direct: 13%, partnership distribution: 9% and group: 12% while product mix of APE stood at linked: 48%; non-linked: 31%, protection: 16%, group: 5%. VNB contribution in FY21 stood at protection: 53.4%, non-linked savings: 24.2% and linked savings at 22.3%.

- Protection pricing to remain unchanged as volume becomes a more important VNB driver in FY22/23. IPRU aims to reach Rs26.5bn VNB in FY23 which would imply an APE of Rs106bn in FY23 at 25% VNB margin. This would necessitate APE CAGR of 31% for IPRU Life between FY21-23E. Maintaining pricing (as indicated by IPRU in protection) can be beneficial to attain volume growth which should also benefit from better traction of new products and distribution channels harnessed in FY21. Total claims on account of Covid for FY21 were Rs4.59bn, while claims net of reinsurance were Rs2.64bn. Additional provision remains at Rs3.32bn towards Covid, not utilised so far but accounted in the EV walk.

- Operating performance has been incrementally positive with (1) positive persistency variation (Rs1.1bn) in FY21 which has also been driven by higher non-par mix which has 13th month persistency of 94%, (2) lower cost ratios (100/80 bps YoY for total /savings business) in FY21 and (3) recovery in APE growth (27% growth in Q4FY21) with health trends witnessed till date in Q1FY22.

- Trading less than 2x FY23E P/EV irrespective of whether VNB falls short of the FY23E target of Rs26.5bn, upgrade from Add to BUY. Based on, 15% APE growth and flattish VNB margins, EV estimate for FY23 turns out to be Rs365.7bn after factoring a negative economic variance possible with increase in interest rates. Meeting the FY23 VNB target is a positive optionality.

Shares of ICICI Prudential Life Insurance Company Ltd was last trading in BSE at Rs.478.3 as compared to the previous close of Rs. 452.25. The total number of shares traded during the day was 1507681 in over 39997 trades.

The stock hit an intraday high of Rs. 503.95 and intraday low of 462.35. The net turnover during the day was Rs. 740651842.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com


Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only. www.equitybulls.com, its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. www.equitybulls.com or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.


Other Headlines:

Maintain BUY on Federal Bank - Pristine asset quality offsets a low provisioning buffer - HDFC Securities

YES SECURITIES on Colgate Palmolive 4QFY21 results - Growth still elusive but margins keep racing ahead

SELL recommendation on Vinati Organics - Robust quarter - HDFC Securities

Maintain ADD on Colgate Palmolive - Beat on all fronts; focus on new launches' success - HDFC Securities

Maintain BUY on Oberoi Realty - Blockbuster quarter - HDFC Securities

Just Dial - Q4FY21 Result Update - YES Securities

Colgate-Palmolive (India) Ltd - Q4FY21 Result Update - YES Securities

Gland Pharma - Q4FY21 Result Update - YES Securities

Oberoi Realty Ltd - Q4FY21 Result Update - YES Securities

Bharti Airtel - Q4 FY21 First cut: Inline - YES Securities

Colgate Palmolive (India) - More of the same - ICICI Securities

Federal Bank - Steady asset quality despite challenges - ICICI Securities

Rossari Biotech - Inorganic growth is key to watch - ICICI Securities

Garden Reach Shipbuilders & Engineers - Execution pickup expected in FY22E - ICICI Securities

Mindspace Business Parks REIT - Q4FY21 - Near-term weakness to persist - ICICI Securities

Oberoi Realty - New launches drive record sales bookings - ICICI Securities

Q4FY21 Company Update - Gokaldas Exports - ICICI Direct

Q4FY21 Result Update - Oberoi Realty - ICICI Direct

Q4FY21 Result Update - Federal Bank - ICICI Direct

Bharti Airtel - Q4FY21 First Cut - ICICI Direct

Maintain BUY on Cipla - Weak quarter, outlook promising - HDFC Securities

Maintain BUY on Larsen & Toubro - Growth returns - HDFC Securities

Escorts - Lowered demand guidance - HDFC Securities

Maintain ADD on Dr. Reddy's Labs - Sputnik V launch to lift near-term outlook - HDFC Securities

AU Small Finance Bank - Showcasing liability strength - cuts SA rate - ICICI Securities

Indigo Paints - The investments thesis is (nearly) intact - ICICI Securities

Greenpanel Industries - Strong growth momentum sustains - ICICI Securities

Aditya Birla Capital - Operating performance gathers momentum; company poised for RoE improvement - ICICI Securities

Dr. Reddy's Laboratories - Steady quarter; outlook intact - ICICI Securities

Cipla - Weak Q4; on track to sustain higher margins - ICICI Securities

Larsen & Toubro - Focus on margins and asset liquidation - ICICI Securities

Voltas - Q4FY21 Result Update - YES Securities

Mphasis - Q4FY21 Result Update - YES Securities

Dr Reddy's Laboratories - Q4FY21 Result Update - YES Securities

Sagar Cements Ltd - Q4FY21 Result Update - YES Securities

Greenpanel Industries Ltd - Q4FY21 Result Update - YES Securities

Larsen & Toubro Ltd - Q4FY21 Result Update - YES Securities

Balkrishna Industries - Growth momentum accelerates - ICICI Securities

Voltas - Healthy growth, uncertain outlook - ICICI Securities

Vedanta - Aluminium, Zinc India continue to drive earnings - ICICI Securities

Q4FY21 Result Update - SKF India - ICICI Direct

Q4FY21 Result Update - Sagar Cements - ICICI Direct

Q4FY21 Result Update - Dr Reddy's Laboratories - ICICI Direct

Q4FY21 Result Update - Dwarikesh Sugar - ICICI Direct

Q4FY21 Result Update - Indian Energy Exchange - ICICI Direct

Q4FY21 Result Update - Balkrishna Industries - ICICI Direct

Q4FY21 Result Update - Avadh Sugar & Energy - ICICI Direct

Q4FY21 Company Update - Vardhman Special Steel - ICICI Direct

Q4FY21 Result Update - Cipla Ltd - ICICI Direct

Q4FY21 Result Update - Larsen & Toubro - ICICI Direct


Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2020